Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals of either gender between the ages of 3months (but weight ≥5 kg) and 12 years who present with symptoms compatible with acute uncomplicated malaria~2. Minimum asexual parasite density of 1000/µl. This will be done at enrolment for all study participants.~3. Fever with an axillary temperature≥ 37.5°C or history of fever within 24hours of presentation~4. Residence within 15 kilometres to the study site.~5. Ability to take drugs orally.~6. Absence of history of ACT intake in the two weeks prior to enrolment~7. A signed informed consent from parents or guardians of the prospective enrollee to participate in the study~Exclusion Criteria:~1. History of allergy to study drugs i.e. artemisinins, lumefantrine and pyronaridine~2. Any concurrent illness that could hamper evaluation of response e.g. bacterial infections, viral infections, severe gastrointestinal disease, malnutrition (weight for height \<70%).~3. Presence of clinical evidence of severe malaria such as prostration, inability to drink or breastfeed, persistent vomiting, convulsion, severe anaemia haemoglobin \<5 g/dl), unarousable coma~4. Patients with known chronic diseases like chronic kidney disease, chronic liver disease, malnutrition, cardiac failure, Sickle Cell haemoglobin (HbSS) etc.~5. Mixed or mono-infection with another Plasmodium species detected by microscopy;~6. presence of severe malnutrition defined as a child aged between 6-60 months whose weight-for-high is below -3 z-score, or has symmetrical oedema involving at least the feet or has a mid-upper arm circumference \< 115 mm).~7. Parent or guardian who in the judgment of the investigator will not comply with protocol in the opinion of the investigator

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 144 Months
- Healthy Volunteers: f

Study Arms:
- Pyramax™ (Type: EXPERIMENTAL): Artesunate-pyronaridine is indicated for the blood-stage treatment of the two dominant strains of malaria: P. falciparum and P. vivax. The medicine is also available in a child-friendly granule formulation to enhance palatability in this vulnerable population. Dosing was administered according to body weight: 5 - \<8kg - one sachet daily for 3 days; 8 - \<15Kg - two sachets daily for 3 days; 15 - \<20 Kg - three sachets daily for 3 days; 20 - \<24 Kg - one tablet daily for 3 days; and 24 - \<45 Kg - two tablets daily for 3 days.
- Coartem™ (Type: ACTIVE_COMPARATOR): We used the standard six-dose regimen of artemether-lumefantrine dispersible tablets twice daily according to body weights. Each dispersible tablet contains 20mg of artemether/120mg of lumefantrine) and the patients were dosed as follows: 5 -\<15Kg one tablet, 15 - \<25 Kg two tablets, 25 - \<35 Kg three tablets, and ≥35 Kg four tablets at the following dosing intervals:~* 0 hour - 1st dose;~* 8 hours - 2nd dose;~* 24 hours - 3rd dose;~* 36 hours - 4th dose;~* 48 hours - 5th dose~* 60 hours - 6th dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).